The Journal article says Pfizer was “showered” with pandemic sales and now the end of the crisis is “dragging the drug maker down”. I don’t agree.Opened the week under $35. WSJ says Pfizer Covid boost is over. What is leadership doing with the billions pocketed during the pandemic boom days?
Your buys are certainly smarter growth investments than PFE. It seems the only investor play for Pfizer is for dividends or to speculate on what company they overpay for next.Sorry, I invest in JnJ, NovoNordisk,Lilly….pfizer stock hasn’t performed well in years despite making millions?/billion off of Covid. Paid way too much for Biohaven
hey they have a plan, focus on DEI and LGBT+ initiatives!The Journal article says Pfizer was “showered” with pandemic sales and now the end of the crisis is “dragging the drug maker down”. I don’t agree.
what is dragging PFE down is the lack of a cogent plan to grow the company and related shareholder value. What company has EVER booked this much in short term unforecasted sales and cannot show any long term value gain? The board has to be corrupt to overlook this sorry performance
*cogent* plan. A business focused plan that would inspire someone to believe in a commercial operation and invest money in expectation of a greater return. In other words, an activity that is currently absent within PFE leadershiphey they have a plan, focus on DEI and LGBT+ initiatives!
hey they have a plan, focus on DEI and LGBT+ initiatives!
You need a little Montgomery in your life.hey they have a plan, focus on DEI and LGBT+ initiatives!
exactly right, that's where this company os focused, ESG, DEI...not growing the business...only reason investors buy our stock is for dividendsIf someone can show me how ESG focus can grow our stock value, I’m reading. From what I see, companies best thrive when they have a sound business strategy that is well understood by employees, public and investors. Those companies have leadership focused on building strategies that meld short term and long term results. Even then, an overly strong focus on non-business centric ESG or other so called “woke” initiatives can cause distraction from the purpose of the business enterprise.
Through our P/E, I don’t see our leaders drive a productive strategy or inspire investor confidence. Investors have multitudes of options to earn a return on their dollars and we simply don’t have the record or forward looking plan to be trusted with their dollars.
If someone can show me how ESG focus can grow our stock value, I’m reading. From what I see, companies best thrive when they have a sound business strategy that is well understood by employees, public and investors. Those companies have leadership focused on building strategies that meld short term and long term results. Even then, an overly strong focus on non-business centric ESG or other so called “woke” initiatives can cause distraction from the purpose of the business enterprise.
Through our P/E, I don’t see our leaders drive a productive strategy or inspire investor confidence. Investors have multitudes of options to earn a return on their dollars and we simply don’t have the record or forward looking plan to be trusted with their dollars.
I am convinced that you sheeple get paid every time you post "woke", or tie some company's negative trajectory on some made-up, BS, fake-ass initiative (in this case, DEI). The bottom line for two decades is this: we were fortunate to have great products that turned into mega blockbusters. Because our pipeline needed support, we bought Parke Davis and later Pharmacia/Upjohn. We would be sucking pond water if it wasn't for Upjohn's Celebrex and oncology meds, and Parke Davis' Lipitor.
Check out our stock prices since, oh, maybe 2004, 2005. Before you sheeple learned the term 'woke' and badly co-opted it. 2004, back when cronyism at HQ ran rampant (anyone remember all the bragging about the "R-gene"?). Most of the senior leadership back then per-walked out of the building, at least one of whom cost us over a billion dollars.
Wow, I’m not sure of what to do with this. I tread lightly for fear of upsetting an elder. Perhaps reading comprehension is no longer your strong suit.
PFE in 2004 closed around $26, was running around $28 mid year 2004. Now, nearly two decades later, PFE bounces around $36. That is not an impressive return over two decades. Even a S&P index fund would have returned nearly 650%. If I’m missing your point, I apologize.
I stand by my point that Pfizer lacks strategic focus and business outcomes that investors desire. The acquisitions you list may have enriched the most senior leaders and the board, but those same people have not translated any of it into substantial long term growth, regardless of who sits at the top. The stock price over time bears out that investors, institutional or individual, trust better options.
What gets me is the diminishing access to providers...nationwide. Hospitals and health care conglomerates buying up clinics and individual practices including their patients. The first thing the new owners do is focusing on profitability, which includes a requirement for the practitioner to see a number of patients to see per year, (determined by a manager who has never seen a single patient, and to go up next year by 10%) and a sign on the front door: "NO PHARMACEUTICAL REPS. TRESPASSERS WILL BE PROSECUTED".
And you are getting back into your car, wondering what to do for the full week.
Strategic Focus... LOL did you learn that term in undergrad? You don't even understand how this company works. It's plan and simple top heavy by design. There are more layers of VPs and GMs than you can count. You do understand that in order for this company to grow like they did some 25 years ago they would need Multiple drugs like the COVID vaccine. MULTIPLE as in 4-5. Not going to happen when you have such a top heavy company. Look back, you keep quoting 2004...go back further... try 1999 when PFE bought Warner Lambert (Parks Davis) who owned Lipitor that was the top. 2004 it was dropping like a rock. We are talking about 2 generations of employees that have been stuck in the stock. The only thing COVID did was give 20 year employees a chance to dump their stock that sat under water for 20 years. Now, employees that came on board pre COVID or during are going to be stuck again for another 20 years. It has nothing to do w/ Strategic FOCUS.. LOL...
have some pudding and a take a nap.
PFE booked record revenues in 2022 and it appears the only plan is to cut costs and buy assets. I am perfectly fine for that cost cutting to look at the top heavy layers that you reference.
Stock is anchored in the mid $30 range, a few bumps up and retreats back. I am only looking for PFE to communicate their plan to capitalize on record revenues and breakout to new price levels.
have some pudding and a take a nap.
PFE booked record revenues in 2022 and it appears the only plan is to cut costs and buy assets. I am perfectly fine for that cost cutting to look at the top heavy layers that you reference.
Stock is anchored in the mid $30 range, a few bumps up and retreats back. I am only looking for PFE to communicate their plan to capitalize on record revenues and breakout to new price levels.
My apologies. I forgot this forum is primarily occupied by disgruntled former reps. I was trying to make some reasonable points about Pfizer’s need to take record unforecasted sales and make more of the company than they have proven able to do.
My points and yours are not dissimilar, you just want to rant. Be well.
My apologies. I forgot this forum is primarily occupied by disgruntled former reps. I was trying to make some reasonable points about Pfizer’s need to take record unforecasted sales and make more of the company than they have proven able to do.
My points and yours are not dissimilar, you just want to rant. Be well.
